Nephrogenic anemia: influence on cardiovascular prognosis and chronic kidney disease progression


Cite item

Full Text

Abstract

Pathogenesis, prognostic significance and treatment strategies in anemia in chronic kidney disease are discussed

References

  1. Mc Clellan W., Aronoff S.L., Bolton W.K., Hood S., Lorber D.L., Tang K.L., Tse T.F., Wasserman B., Leiserowitz M. The prevalence of anemia in patients with chronic kidney disease. Curr. Med. Ress. Opion. 2004; 20: 1501-1510
  2. Orbador G.T., Roberts T., St Peter W.L., Frazier E., Pereira B.J., Collins A.J. Trends in anemia at initiator of dialysis in the United States. Kidney Int. 2001; 60: 1875-1884
  3. Revised European Best Practice Guidelines for the Management of anemia in Patients with Cronic Renal Failure. Nephrol. Dial. Transplant. 2004; 19 [Suppl. 2]: ii2-ii45 4. Российские национальные Рекомендации по диагностике и лечению анемии при хронической болезни почек. Анемия. 2006; 3: 3-18
  4. Милованов Ю.С., Козловская Л.В., Николаев А.Ю., Фомин В.В., Милованова Л.Ю. Анемия у больных с хронической почечной недостаточностью. Леч. врач. 2005; 7: 16-21
  5. Милованова Л.Ю., Николаев А.Ю., Козлова Т.А. и др. Прогностическое значение ранней коррекции анемии у больных хронической почечной недостаточностью. Нефрол. и диал. 2004; 1: 54-57
  6. Добронравов В.А., Смирнов А.В. Анемия и хроническая болезнь почек. Анемия. 2005; 2: 2-8
  7. Bansal N., Tighiouart H., Weiner D., Griffith J., Vlagopoulos P., Salem D., Levin A., Sarnak M. Anemia as a Risk Factor for Kidney Function Decline in Individuals With Heart Failure. Am. J. Cardiol. 2007; 99: 11-37-1142
  8. Tong P.C., Kong A.P., So W.Y., Ng M.H., Yang X., Ng M.C., Ma R.C., Ho C.S., Lam C.W., Chow C.C., Cockram C.S., Chan J.C.: Hematocrit, independent of chronic kidney disease, predicts adverse cardiovascular outcomes in clinese patients with type 2 diabetes. Diabetes Care. 2006; 29: 2439-2444
  9. Li S., Foley R.N., Collins A. J. Anemia and cardiovascular disease, Hospitalization, and stage renal disease, and death in older patients with chronic kidney disease. Int. Urol. Nephrol. 2005; 37(2): 395-402
  10. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update. Am. J. Kidney Dis. 2001; 37 (suppl. 1): 182-238
  11. Besarab A., Goodkin D.A., Nissenson A.R. The Normal Hematocrit. Study Follow-up. N. Engl. J. Med., 2008; 358: 433-434
  12. Cody J., Daly C., Campbell M. et al. Recombinant human erythropoietin for chronic renal failure anemia in pre-dialysis patients. Cochrane Database Syst. Rev. 2005; 3: СД 003266
  13. Швецов М.Ю., Иванов А.А., Попова О.П., Кузнецова А.В., Рамеева А.С. Взаимосвязи почечной экспрессии фактора, индуцируемого гипоксией, с выраженностью нефросклероза и анемии при хроническом гломерулонефрите. Клин. Мед. 2009; 2: 66-70
  14. Keithi-Reddy B.R., Addabbo F., Patel T.V. et al. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int. 2008; 74(6): 782-790
  15. Roth D. Smith R., Schulman G. et al. Effect of rhEPO on renal funtion in predislysis patients. Am. J. Kidney Dis. 1994; 24: 777-784
  16. Hue J.L., St Peter W.R., Ebben J.P. et al. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am. J. Kidney Dis. 2002; 40: 1153-1161
  17. Cody J., Daly C., Campbell M. et al. Recombinant human erythropoietin for chronic renal failure anemia in pre-dialysis patients (Cochrane Review). In: The Cochrane Library. Issue 3, 2003. Update Software, Oxford
  18. Thorp M.L., Johnson E.S. Effect of anemia on mortality, Cardiovascular Hospitalizations and End Stage Renal Disease among patients with chronic renal desease. Nephrology. 2009; 14: 240-246.
  19. Hsu C.Y., McCulloch C.E., Curhan G.C. et al. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J. Am. Soc. Nephrol. 2002; 13: 504-510
  20. Lefebvre P., Vekeman F., Sarokhan B., Enny C., Provenzano R., Cremieux P.Y. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease recriving epoetin alfa. Curr. Med. Res. Opion. 2006; 22: 1929-1937.
  21. Ермоленко В.М., Филатова Н.Н. Физиология метаболизма железа. Анемия. 2004; 1: 3-10
  22. Ермоленко В.М., Хасабов Н.Н., Михайлова Н.А. Рекомендации по применению препаратов железа у больных с хронической почечной недостаточностью. Анемия. 2005; 2: 9-25
  23. Шостка Г.Д. Дефицит железа. Анемия. 2004; 1: 11-18
  24. Шеффер Р.М., Гаше К., Хух Р., Краффт А. Железное письмо: рекомендации по лечению железодефицитной анемии. Анемия. 2005; 2: 37-45
  25. Фесюк А.Ф., Мердик А.И., Борисова Е.В. и др. Применение препарата «венофер» для коррекции дефицита железа у пациентов, находящихся на программном гемодиализе. Тер. архив. 2003; 8: 59-61
  26. Козловская Л.В., Милованов Ю.С., Милованова С.Ю. Особенности течения и лечения анемии у больных с поражением почек при системных заболеваниях. Клиницист. 2008; 2: 16-20
  27. Drueke T.B., Locatelli F., Cyne N. et al. CREATE Investidators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New. Engl. J. Med. 2006; 355(20): 2071-2084
  28. Singh A.K., Szczech L., Tang K.L. et al. CHOIR Investidators. Correction of anemia with epoetin alfa of chronic kidney disease. New. Engl. J. Med. 2006; 355(20): 2085-2098
  29. Besarab A, Bolton W.K., Browne J.K. The effects of normal as compared with low are receiving hemodialysis and epoetin. N. Engl. J. Med. 1998; 339: 584-590
  30. Saueressing U., Sapede C., De Cock E., Staff time and costs for amemia management wth erytropoietic stimulating agents in patients on hemodialysis. Nephrol. Dioal. Transplant. 2007; 22(Suppl 6): vi347-vi348
  31. Fishbane S., Berns J.S. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005; 68: 1337-1343
  32. Macdougall I.C., Gray S.J., Elston O., Breen C., JenkinsB., Browne J., Egrie J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J. Am. Soc. Nephrol. 1999; 10: 2392-2395
  33. Phrommintikul A., Haas S.J., Elsik M., Krum H. Mortality and target haemoglobin concentrations in anemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007; 369:381-388
  34. Strippoli G.F., Navaneethan S.D., Craig J.C. Hemoglobin and hematocrit targets for the anemia of chronic kidney disease. Cochrane Database Syst. Rev. 2006; 18(40): CD003967
  35. Ермоленко В.М., Козловская Л.В., Милованов Ю.С. Анемия при хронической болезни почек. Нефрология: национальное руководство/под ред. Н.А. Мухина. М.: ГЭОТАР-Медиа. 2009; 191-203
  36. Aranesp Summary of Product Characteristics. Shire Pharmaceuticals Ltd. July. 2006
  37. MIRCERA Summary of Product Characteristics. Roche Products Ltd. July. 2007
  38. Шило В.Ю. Мирцера - новая эра в лечении ЭПО-дефицитной анемии. Нефрол. и диал. 2008; (3-4): 192-198
  39. Halstenson C.E., Macres M., Kats S.A., Schnieders J.R., Watanabe M., Sobota J.T., Abraham P.A. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin. Pharmacol. Ther. 1991; 50: 702-712
  40. Gross A.W., Lodish H.F. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J. Biol. Chem. 2006: 281: 2024-2032
  41. Klinder M., Arias M., Vargremezis W., Besarab A., Sulowicz W., Gerntholtz T., Dougherty F.C. C.E.R.A. (continuous erythropoietin receptor activator) administered at extended administration intervals corrects Hb levels in patients with chronic kidney disease on dialysis. J. Am. Soc. Nephrol. 2006; 17: 620A (abstract SA-PO212)
  42. Dean B.B., Dylan M., Gano A. Jr., Knight K., Ofman J.J., Levine B.S.: Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr. Med. Res. Opin. 2005; 21: 981-987
  43. Roche data on file. Data on file. 2007
  44. Sulowicz W., Locatelli F., Ryckenlynck J-P., Balla J., Csiky B., Harris K., Ehrhard P., Beyer U., on behalf of the PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic Kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin. J. Am. Soc. Nephrol. 2007; 2: 637-646.
  45. Милованов Ю.С., Лысенко Л.В., Милованова С.Ю., Добросмыслов И.А. Препараты эпоэтина и железа в лечении анемии у больных хронической болезнью почек на преддиализных стадиях и при проведении программного гемодиализа. Мед. совет. 2009; 1: 13-19
  46. Fishbane S., Ungureanu V., Maesaka et al. The safety of intravenous iron dextran in hemodialysis patients. Am. J. Kidney Dis. 1996; 28: 529-534
  47. Hunsicker L.G.: The consequences and costs of chronic kidney disease before ESRD. J. Am. Soc. Nephrol. 2004; 15: 1363-1364
  48. Heung M., Mueller B.A., Segal J.H. Optimising Anemia Managament in Hospitalized patients with End-Stage renal Disease the Annals of Pharmacotherapy. 2009; 43(20): 276-282
  49. Singh A.K., Szczech L., Tang K.L. et al. CHOIR Investidators. Correction of anemia with epoetin alfa of chronic kidney disease. New. Engl. J. Med. 2006; 355(20): 2085-2098
  50. Fishbane S. Erythropoiesis-stimulating agent treatment with full anemia correction: a new perspective. Kidney Int. 2009; 75(4): 358-365
  51. Hampl H., Riedel E. Cardiac Disease in the Dialysis Patients: Good, Better< best Clinical Practice. Blood purify. 2009; 27: 99-113
  52. Ebben J.P., Gilbertson D.T., Foley R.N., Collins A.J. Hemoglobin level variability: assotiation with comorbidity, intrcurrent events, and hospitalizations. Clin. J. Am. Soc. Nephrol. 2006: 1: 1205-1210
  53. Gilbertson D., Ebben J., Collins A. The effects of hemoglobin variability on hospitalization and mortality. Nephrol. Dial. Transplant. 2006; 21 (suppl 4): iv169 (abstract SP458)
  54. Feldman H.I., Israni R.K., Yang W., Fishbane F., Joffe M. Hemoglobin variability and mortality among hemodialysis patients. J. Am. Soc. Nephrol. 2006: 17: 583A (abstract SA-PO034)
  55. Collins A.J., Brenner R.M., Ofman J.J. et al. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am. J. Kidney Dis. 2005; 46: 481-488
  56. Gilbertson D.T., Ebben J.P., Foley R.N., Weinbandl E.D., Bradbury B.D., Collins A.J. Hemoglobin level variability: association with mortality. Clin. J. Am. Soc. Nephrol. 2008; 3(10: 133-138
  57. Levin N.W., Fishbane S., Zeig S., Nassar G., Moran J., Villa G., Dougherty F.C. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks or once monthly maintains hemoglobin levels in patients with chronic kidney disease on dialysis. Nephrol. Dial. Transplant. 2006; 21 (Suppl 4): iv11 (abstract SO023)
  58. Locatelli F., Villa G., Francisco A.L.M., Albertazzi A., Adrogue H.J., Dougherty F.C., Beyer U; on behalf of the BA 16286 Study Investigators. Effect of a continuous erythropoietin receptor activator C.E.R.A. on stable hemoglobin in patients with chronic kidney disease on dialysis once monthly administration. Curr. Med. Res. Opin. 2007; 23: 969-979
  59. Kovesdy C.P., Trivedy B.K., Kalantar-Zaden K., Anderson J.E. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 2006; 69: 560-564
  60. Gouva C., Nicolopoulos P., Ionnidis J., Siamopoulos K. Teating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004; 66: 753-760

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies